Infinium Global Research Diabetic Neuropathy -IGR | Page 4

2023. Whereas, Asia Pacific expected to emerge as most dynamic region with highest CAGR
owing to increased governmental support, and increased healthcare expenditure. The report
covers the analysis of global as well as regional markets of the Diabetic Neuropathy market.
Moreover the report provides deep insights on demand forecasts, market trends and micro and
macro indicators. In addition, this report provides insights on the factors that are driving and
restraining the demand globally as well as regionally. Moreover, Infinium Global Research-
Growth Matrix (IGR- Growth Matrix) given in the report brings an insight on the investment
areas that existing or new market players can consider.
The report provides insights into the market using analytical tools such as Porter’s five forces
analysis and value chain analysis of Diabetic Neuropathy. Moreover, the study highlights
current market trends and provides forecast from 2017 to 2023. We also have highlighted
future trends in the Diabetic Neuropathy that will impact the demand during the forecast period.
The companies covered in the report include Pfizer Inc, Janssen Pharmaceuticals, Inc, Eli Lilly
and Company, ACTAVIS, Cephalon Inc, MEDA Pharma GmBH & Co. KG, GlaxoSmithKline,
NeuroMetrix, Inc, Johnson and Johnson.